These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34743366)

  • 21. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 22. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study.
    Torres T; Paiva-Lopes MJ; Gonçalo M; Claro C; Oliveira M; Gomes J; Vieira AP; Amoedo P; Alpalhão M; Nogueira M; Santiago F; Henrique M; Amaro C; Esteves T; Alves J; Cerejeira D; Mendes-Bastos P; Pestana M; Ramos L; Rocha J; Carvalho R; Teixeira L; Selores M; Mota A; Filipe P;
    J Dermatolog Treat; 2022 Aug; 33(5):2554-2559. PubMed ID: 35083945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study.
    Yang DY; Li L; Lu T; Jing WW; Liu X; Li XL
    Arch Dermatol Res; 2023 Apr; 315(3):467-472. PubMed ID: 35989340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.
    Narla S; Silverberg JI; Simpson EL
    J Am Acad Dermatol; 2022 Mar; 86(3):628-636. PubMed ID: 34126094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
    Chia SY; Wee LWY; Koh MJA
    Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis.
    Nettis E; Patella V; Lombardo C; Detoraki A; Macchia L; Di Leo E; Carbonara M; Canonica GW; Bonzano L
    Allergy; 2020 Oct; 75(10):2653-2661. PubMed ID: 32424957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
    Agnihotri G; Shi K; Lio PA
    Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
    Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
    Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study.
    Zhou X; Yang G; Chen X; Zhang L
    Drugs Aging; 2023 Oct; 40(10):933-940. PubMed ID: 37610613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid resolution of diffuse warts following initiation of dupilumab for severe atopic dermatitis.
    Netravali IA; Sockler PG; Heimall J; Treat JR
    Pediatr Dermatol; 2024; 41(2):275-278. PubMed ID: 37680146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dupilumab use in atopic dermatitis and beyond in skin diseases.
    Fourzali K; Golpanian RS; Yosipovitch G
    Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study.
    Berna-Rico E; Fiz-Benito E; Busto-Leis JM; Servera-Negre G; de Lucas-Laguna R; Feito-Rodriguez M
    Dermatology; 2024; 240(2):337-342. PubMed ID: 38035567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series.
    Ruiz-Villaverde R; Dominguez-Cruz J; Armario-Hita JC; Martinez-Pilar L; Alcantara-Luna S; Pereyra-Rodriguez JJ
    Dermatol Ther; 2019 Jul; 32(4):e12931. PubMed ID: 30980485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
    Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
    Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children.
    Wang M; Gao XH; Zhang L
    Drug Des Devel Ther; 2024; 18():941-951. PubMed ID: 38560522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review.
    Neagu N; Dianzani C; Avallone G; Dell'Aquila C; Morariu SH; Zalaudek I; Conforti C
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):820-835. PubMed ID: 35122335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.